Results 61 to 70 of about 40,110 (297)

LmxM.22.0250-Encoded Dual Specificity Protein/Lipid Phosphatase Impairs Leishmania mexicana Virulence In Vitro

Pathogens, 2019
Protein phosphorylation/dephosphorylation is an important regulatory mechanism that controls many key physiological processes. Numerous pathogens successfully use kinases and phosphatases to internalize, replicate, and survive, modifying the host′s
Natalya Kraeva, Tereza Leštinová, Aygul Ishemgulova, Karolina Majerová, Anzhelika Butenko, Slavica Vaselek, Julia Bespyatykh, Arzuv Charyyeva, Tatiana Spitzová, Alexei Yu. Kostygov, Julius Lukeš, Petr Volf, Jan Votýpka, Vyacheslav Yurchenko   +13 more
doaj   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Dual-specificity MAP kinase phosphatases in health and disease [PDF]

, 2018
Source at https://doi.org/10.1016/j.bbamcr.2018.09.002.It is well established that a family of dual-specificity MAP kinase phosphatases (MKPs) play key roles in the regulated dephosphorylation and inactivation of MAP kinase isoforms in mammalian cells ...
Abdul Rahman, Abraham, Al-Mutairi, Alessi, Ananieva, Andrew M. Kidger, Arkell, Arthur, Barthas, Bertin, Brondello, Buffet, Cadalbert, Camps, Camps, Cao, Carey, Caunt, Charles, Chattopadhyay, Chen, Chi, Christie, Chu, Clark, Collins, Collins, Cornell, Courtois-Cox, Degl'Innocenti, Dhillon, Dickinson, Dickinson, Dickinson, Dorfman, Dowd, Duric, Eblaghie, Ekerot, Emanuelli, Fan, Farooq, Feng, Ferguson, Flach, Franklin, Fukuda, Furukawa, Furukawa, Gaestel, Groom, Grumont, Guan, Guermonprez, Haagenson, Haigis, Hammer, Hartmann, Hirosumi, Holmes, Hommo, Hou, Hrustanovic, Hsiao, Hsu, Huang, Huang, Huang, Ishibashi, Jeffrey, Jeong, Jiao, Jono, Kang, Karlsson, Kawakami, Kesarwani, Keyse, Keyse, Keyse, Kidger, Kim, Kim, King, Kondoh, Korotchenko, Kortum, Kovanen, Kovanen, Kreeger, Krishnan, Kucharska, Kutty, Kwak, Lakbakbi El Yaagoubi, Lawan, Lawan, Lee, Li, Li, Lin, Lin, Liu, Liu, Low, Lu, Maier, Mandl, Martell, Masuda, Matsuguchi, Matta, McGuire, Menyhart, Messina, Min, Misra-Press, Mourey, Muda, Muda, Muda, Niedzielska, Niedzielska, Nunes-Xavier, Okudela, Ole-Morten Seternes, Owens, Packer, Parveen, Perander, Pest, Pfender, Pfuhlmann, Phuchareon, Png, Pramanik, Qian, Qian, Raingeaud, Reddy, Rohan, Roth, Ruan, Rushworth, Salojin, Saltiel, Sanchez-Perez, Schmid, Sherrin, Shi, Shi, Shi, Shin, Shojaee, Slack, Small, Small, Smallie, Smith, Staples, Stephen M. Keyse, Stewart, Sun, Tanoue, Tanoue, Tao, Taylor, Theodosiou, Theodosiou, Thomas, Tischer, Togel, Tonnetti, Valente, Valledor, Vandevyver, Vartanian, Voight, Wang, Wang, Ward, Wittig-Blaich, Woods, Wu, Wu, Wu, Xu, Xu, Xu, Xu, Yasuda, Ye, Yu, Yu, Zega, Zhang, Zhang, Zhang, Zhang, Zhang, Zhao, Zhao, Zhou, Zhou   +203 more
core   +3 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Reversible control of kinase signaling through chemical-induced dephosphorylation

Communications Biology
The coordination between kinases and phosphatases is crucial for regulating the phosphorylation levels of essential signaling molecules. Methods enabling precise control of kinase activities are valuable for understanding the kinase functions and for ...
Ying Sun, Rihong Zhou, Jin Hu, Shan Feng, Qi Hu   +4 more
doaj   +1 more source

DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.

PLoS ONE, 2017
BackgroundMolecular alterations of the MAPK pathway are frequently observed in papillary thyroid carcinomas (PTCs). It leads to a constitutive activation of the signalling pathway through an increase in MEK and ERK phosphorylation.
Camille Buffet, Karine Hecale-Perlemoine, Léopoldine Bricaire, Florent Dumont, Camille Baudry, Frédérique Tissier, Jérôme Bertherat, Beatrix Cochand-Priollet, Marie-Laure Raffin-Sanson, Françoise Cormier, Lionel Groussin   +10 more
doaj   +1 more source

ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer

Cells, 2021
The RAF/MEK/ERK signaling pathway regulates diverse cellular processes as exemplified by cell proliferation, differentiation, motility, and survival. Activation of ERK1/2 generally promotes cell proliferation, and its deregulated activity is a hallmark ...
Reiko Sugiura, Ryosuke Satoh, Teruaki Takasaki   +2 more
doaj   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Expression levels of some genes in the MAPK pathway (DUSP1, DUSP2, DUSP4, DUSP6 and DUSP10) in eyelid tumor tissue

Türk Biyokimya Dergisi
To control mitogen-activated protein kinases (MAPK) signaling pathways involved in the onset and progression of cancer, dual specificity phosphatases (DUSPs/MKP) are essential.
Ozmen Esma, Tas Ayca, Akin Dilara Fatma, Erdogan Haydar, Silig Yavuz   +4 more
doaj   +1 more source

Bioengineering models of cell signaling [PDF]

, 2000
Strategies for rationally manipulating cell behavior in cell-based technologies and molecular therapeutics and understanding effects of environmental agents on physiological systems may be derived from a mechanistic understanding of underlying signaling ...
Asthagiri, Anand R., Lauffenburger, Douglas A.   +1 more
core   +1 more source